With the explosion of generative AI and the emergence of LLMs over the last year, what are the ramifications across the clinical document landscape? Increasingly, life sciences firms are leveraging content automation solutions to maximize the efficiency, accuracy, and standardization of reporting and writing processes.
In this session, Tim Martin, Executive VP of Product at Yseop, will dive into where artificial intelligence fits into the clinical document landscape and how new drugs will be discovered using generative AI techniques over the upcoming years. He will map out:
- The benefits of deploying generative AI and natural language generation (NLG) to automate reporting for improved clinical writing.
- Why generative AI promises to reduce costs and accelerate time to market in drug discovery.
- Results from pharmaceutical companies that have implemented this technology.
Yseop is an international AI software corporation that specializing in developing natural language generation (NLG) technology. Its primary enterprise software platform, Yseop Copilot, aids premier life science organizations worldwide in accelerating the automation of data analysis and report generation, bringing drugs to market faster.